Merck's Covid-19 pill active against Omicron in lab studies
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 29, 2022
SUNDAY, MAY 29, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Merck's Covid-19 pill active against Omicron in lab studies

Coronavirus chronicle

Reuters
29 January, 2022, 08:50 am
Last modified: 29 January, 2022, 01:45 pm

Related News

  • Japan's Shionogi says Covid-19 pill shows rapid clearance of virus
  • Demand for Pfizer's Covid pills lags around the world
  • New Covid pills are needed as much as ever
  • Britain to start rolling out Pfizer Covid pill next month
  • US FDA set to authorise Pfizer, Merck Covid-19 pills this week

Merck's Covid-19 pill active against Omicron in lab studies

Pfizer said in December lab data suggested  its drug Paxlovid retained its effectiveness against Omicron

Reuters
29 January, 2022, 08:50 am
Last modified: 29 January, 2022, 01:45 pm
An experimental Covid-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Photo: Reuters
An experimental Covid-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Photo: Reuters

Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral Covid-19 drug molnupiravir was active against the fast-spreading Omicron variant.

The data evaluated the antiviral activity of molnupiravir and other Covid-19 antiviral agents against Covid-19 variants of concern. Molnupiravir is yet to be studied against Omicron in human studies, the companies said.

Molnupiravir and a rival oral pill from Pfizer Inc were authorized in the United States in December and are considered as important tools against Omicron.

Pfizer said in December lab data suggested  its drug Paxlovid retained its effectiveness against Omicron.

Merck said earlier this month its pill has a mechanism  that can work against Omicron and any other variant.

Molnupiravir has been authorized for use in more than 10 countries, including the United States, United Kingdom and Japan.

Top News / World+Biz

Merck / Covid pill

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bankers unhappy with uniform exchange rate
    Bankers unhappy with uniform exchange rate
  • Finance projects export fall, remittance rise
    Finance projects export fall, remittance rise
  • Road crash kills 10 in Barishal 
    Road crash kills 10 in Barishal 

MOST VIEWED

  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Shanghai takes further steps towards reopening, Beijing eases Covid curbs
  • Photo: Collected
    US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    'Tomorrow will be better': Shanghai inches towards Covid re-opening
  • North Korea says new fever cases under 100,000 as virus fight heats up
    North Korea says new fever cases under 100,000 as virus fight heats up
  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings

Related News

  • Japan's Shionogi says Covid-19 pill shows rapid clearance of virus
  • Demand for Pfizer's Covid pills lags around the world
  • New Covid pills are needed as much as ever
  • Britain to start rolling out Pfizer Covid pill next month
  • US FDA set to authorise Pfizer, Merck Covid-19 pills this week

Features

Rebecca Ivey. Illustration: TBS

How China’s efforts are advancing global development

33m | Thoughts
Women voluntarily joined the peaceful procession and protested by wearing clothing of their own choice. Photo: Trishia Nashtaran

The unhealthy obsession with what women wear

10h | Panorama
Illustration: Freepik

Bangladesh is on the verge of destigmatising menstruation

14h | Features
Photo: Collected

The death of Davos?

20h | Panorama

More Videos from TBS

Photo: TBS

Tips to help you become a successful lawyer

58m | Videos
People bid adieu to Abdul Gaffar Chowdhury

People bid adieu to Abdul Gaffar Chowdhury

1h | Videos
Photo: TBS

Harassment over 'indecent clothing': Women gather at Narsingdi railway station to protest, show solidarity

1h | Videos
Attorney General's suggestion to reduce case clutter

Attorney General's suggestion to reduce case clutter

14h | Videos

Most Read

1
Bangladesh Bank GM, DGM’s designation changed
Banking

Bangladesh Bank GM, DGM’s designation changed

2
Corporates go cashless…tax cut on cards
NBR

Corporates go cashless…tax cut on cards

3
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

4
British International Investment (BII) CEO Nick O’Donohoe. Illustration: TBS
Economy

BII to invest $450m in Bangladesh in 5 years

5
Representational image. Picture: Pixabay
Economy

Govt raises regulatory duty to discourage imports of 130 products

6
Photo: Collected
Industry

Spanish recycled cotton producer opens new facility in Bangladesh

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab